Mission

Empower health research through your dedicated sponsorship.

The Montalcino Aortic Consortium’s mission is to enhance the care and improve outcomes for individuals with Hereditary Thoracic Disease (HTAD) via precision medicine through collaborative research and shared expertise.

To advance the understanding of diagnosis, the natural history of disease, discovering genetic contributors and modifiers, and supporting the development of innovative treatments.

The objectives of the consortium are:

To establish and update the diagnostic criteria for a growing list of conditions, now more than two dozen, that affect the thoracic aorta and its arterial branches;
To understand the natural and clinical histories of these conditions;
To discover additional genetic variations that predispose to HTAD;
To explore the reasons for variable expression of these genetic variations, especially modifier genes;
To discover and test new approaches to treatment; and
To facilitate collaborations in all of these endeavors.